Portal de Periódicos da CAPES

Associated Factors for Mortality in a COVID-19 Colombian Cohort by Epidemic Wave: Is the Predominance of Mu Variant Relevant?

2022; RELX Group (Netherlands); Linguagem: Inglês

10.2139/ssrn.4297049

1556-5068

Carlos Álvarez, Sandra Valderrama, Ronaldo Silva, Ilich Herbert De La Hoz Siegler, Fabio Andrés Varón Vega, Samuel Martínez-Vernaza, Tatiana Ordoñez Blanco, Mónica Padilla, María Lucía Mesa-Rubio, Laura Carmenza Castañeda Pascagaza, José Antonio Rojas, Juan Sebastián Bravo Ojeda, Jaime Villa, Julio Alberto Chacón Sarmiento, Nancy Yomayusa, Sandra Patiño, Katherine Gómez-Nieto, Viviana Lorena Martínez Pinzón, Angélica María Ramírez Cogollo, Carlos Toloza, Melissa Diaz-Puentes, Alejandra Cañas-Arboleda, Margarita Manrique-Andrade, Roberto Tarud Ayub, María José López Mora, María Julieta Pachón Espinosa, Jorge Alberto Cortés, Laura Catalina Sánchez, Kelly Acevedo, Paola Rengifo, Ginna Tambini, Silvia Bertagnolio, Janet Dı́az, Soe Soe Thwin, Ludovic Revéiz,

COVID-19 epidemiological studies

Background: The third epidemic wave reported the greatest number of deaths related to SARS-CoV-2 in Colombia. In this wave, the Mu variant was predominant in 75% of the cases. Therefore, we evaluated the association between Colombia's third wave and COVID-19 all-cause in-hospital mortality.Methods: In this retrospective cohort, we included hospitalized patients ≥18 years with SARS-CoV-2 infection between March 2020 to September 2021 in ten hospitals from three cities in Colombia. Description analysis, survival, and multivariate Cox regression analyses were performed to evaluate the association between the third epidemic wave and in-hospital mortality.Findings: A total of 25,371 patients were included. The age-stratified time-to-mortality analysis showed differences according to epidemic waves in patients ≥75 years (log-rank test p=0.012). In the multivariate Cox analysis, the third wave was not associated with increased mortality relative to the first wave (aHR 0.95; 95%CI 0.84-1.08), but there was an interaction between age ≥75 years and the third wave finding a lower HR for mortality (aHR 0.56, 95%CI 0.36-0.86).Interpretation: We did not find an increase in in-hospital mortality during the third epidemic wave in which the Mu variant was predominant in Colombia. The reduced hazard in mortality in patients ≥75 years hospitalized in the third wave could be explained by the high coverage of SARS-CoV-2 vaccination in this population and patients with underlying conditions. Funding Information: The World Health Organization funded this study.Declaration of Interests: CAM declares financial support from the World Health Organization to conduct the Solidarity Clinical Trial in Colombia. Also declares personal fees from Pfiezer, Aztra Zeneca and GSK, outside of the production of this study. SLVB declares personal fees as a member of the advisory boards from GSK, MSD, Biotoscana, outside of the production of this study. JACL declares Research Grant for antibiotic and antifungal stewardship for Pfiezer, outside of the production of this study. The rest of the authors don’t disclose potential conflict of interests.Ethics Approval Statement: The study was approved by each IRB or Ethics Committee of the participant institutions. All the methods in this study were conducted following national (Resolution 8430 of 1993, stated by The Colombian Health Ministry) and international (The declaration of Helsinki) standards. Informed consent was not required since there were no interventions performed.